EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors

Christine M. Fillmore, Chunxiao Xu, Pooja T. Desai, Joanne M. Berry, Samuel P. Rowbotham, Yi Jang Lin, Haikuo Zhang, Victor E. Marquez, Peter S. Hammerman, Kwok Kin Wong, Carla F. Kim

Research output: Contribution to journalArticlepeer-review

183 Scopus citations

Abstract

Non-small-cell lung cancer is the leading cause of cancer-related death worldwide. Chemotherapies such as the topoisomerase II (TopoII) inhibitor etoposide effectively reduce disease in a minority of patients with this cancer; therefore, alternative drug targets, including epigenetic enzymes, are under consideration for therapeutic intervention. A promising potential epigenetic target is the methyltransferase EZH2, which in the context of the polycomb repressive complex 2 (PRC2) is well known to tri-methylate histone H3 at lysine 27 (H3K27me3) and elicit gene silencing. Here we demonstrate that EZH2 inhibition has differential effects on the TopoII inhibitor response of non-small-cell lung cancers in vitro and in vivo. EGFR and BRG1 mutations are genetic biomarkers that predict enhanced sensitivity to TopoII inhibitor in response to EZH2 inhibition. BRG1 loss-of-function mutant tumours respond to EZH2 inhibition with increased S phase, anaphase bridging, apoptosis and TopoII inhibitor sensitivity. Conversely, EGFR and BRG1 wild-type tumours upregulate BRG1 in response to EZH2 inhibition and ultimately become more resistant to TopoII inhibitor. EGFR gain-of-function mutant tumours are also sensitive to dual EZH2 inhibition and TopoII inhibitor, because of genetic antagonism between EGFR and BRG1. These findings suggest an opportunity for precision medicine in the genetically complex disease of non-small-cell lung cancer.

Original languageEnglish
Pages (from-to)239-242
Number of pages4
JournalNature
Volume520
Issue number7546
DOIs
StatePublished - Apr 9 2015

Bibliographical note

Funding Information:
Acknowledgements We thank the Kim laboratory, F. Luo, P. Louis, K. Harrington, X. Wang and J. Brainson for technical assistance and discussions, and J. Crabtree, D. Hargreaves, C. Kadoch, L. Zon, K. Cichowski, M. Enos, S. Orkin, A. Gutierrez and C. Roberts for discussions. This work was supported in part by the Ladies Auxiliary to the Veterans of Foreign Wars, PF-12-151-01-DMC from the American Cancer Society, and the Uniting Against Lung Cancer Young Investigator Award supported by Meryl Bralower (C.M.F.), Boston University Undergraduate Research Opportunities Program (P.T.D.), RO1 HL090136, U01 HL100402 RFA-HL-09-004, American Cancer Society Research Scholar Grant RSG-08-082-01-MGO, the V Foundation for Cancer Research, aBasilO’Conner MarchofDimesStarterAward,the Harvard StemCellInstitute,and the Lung Cancer Research Foundation (C.F.K.), the National Institutes of Health (NIH) grants CA122794, CA140594, CA163896, CA166480, CA154303 and CA120964 (K.K.W.), the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (V.E.M.), and the NIH grant K08 CA163677 (P.S.H.).

Publisher Copyright:
©2015 Macmillan Publishers Limited. All rights reserved.

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors'. Together they form a unique fingerprint.

Cite this